Minerva Neurosciences Topline Results of Major Depression Phase 2b Trial

• MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpoints
• MIN-117 was generally well-tolerated with a safety profile comparable to placebo
• Company hosted conference call at 5:00 p.m. today.  Minerva held a conference call and live audio webcast on December 18, 2019 at 5:00 p.m. Eastern Time.  To participate, please dial (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and refer to conference ID number 3296395.  The live webcast can also be accessed under “Events and Presentations” in the Investors and Media section of Minerva’s website at ir.minervaneurosciences.com.  The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.

https://www.globenewswire.com/news-release/2019/12/18/1962474/0/en/Minerva-Neurosciences-Reports-Topline-Results-From-Phase-2b-Trial-of-MIN-117-in-Major-Depressive-Disorder.html